BioSig Technologies, Inc.

  • Home
  • About BioSig
    • Overview
    • Leadership
    • Bioelectronic Medicine
    • Partnerships
  • Pure EP
    • Our Solution
    • Publications
    • Physician Insights
  • News & Media
    • Overview
    • Press Releases
    • BioSig in the News
    • Presentations
    • Events
    • CEO Blog
  • Investors
    • Investor Relations
    • Overview
    • News / Events
    • Press Releases
    • IR Calendar
    • Email Alerts
    • Company Info
    • Profile
    • Presentations
    • Management Team
    • Contacts
    • FAQ
    • Financial Info
    • Balance Sheet
    • Income Statement
    • Cash Flow
    • Financial Results
    • Stock Data
    • Quote
    • Charts
    • Historical Data
    • Analyst Coverage
    • SEC Filings
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
    • Governance
    • Board of Directors
    • Board Committees
    • Governance Documents
  • Contact
Investors

Investors

  • Overview
  • News / Events
    • Press Releases
    • IR Calendar
    • Email Alerts
  • Company Info
    • Profile
    • Presentations
    • Management Team
    • Contacts
    • FAQ
  • Financial Info
    • Balance Sheet
    • Income Statement
    • Cash Flow
    • Financial Results
  • Stock Data
    • Quote
    • Charts
    • Historical Data
    • Analyst Coverage
  • SEC Filings
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Board of Directors
    • Board Committees
    • Governance Documents
  • Investor Tools
    • Email Alerts
    • Fact Sheet
    • Contacts
    • RSS News Feed

Press Releases

  • News / Events

  • Press Releases
  • IR Calendar
  • Email Alerts

BioSig Technologies, Inc Closes $17.5 Million Common Stock Offering

June 29, 2020

BioSig Technologies, Inc. Announces $17.5 Million Common Stock Only Registered Direct Offering

June 24, 2020

ViralClear Partners with Catalent on Potential Treatment for COVID-19

June 22, 2020

ViralClear Opens Enrollment with First Patient Dosing in Phase II Human Trial of Anti-Viral MMPD Oral Solution for Treatment of COVID-19

June 17, 2020

Reminder - BioSig Subsidiary, ViralClear to Host Conference Call on June 9th to Discuss Upcoming and Recent Developments for Phase II Human Clinical Trials of its Broad-Spectrum Oral Anti-Viral Candidate for Treatment of COVID-19

June 8, 2020

ViralClear adds St. David's HealthCare in Austin, Texas, to its Planned Phase II trial for its Broad-Spectrum Oral Anti-Viral Candidate for COVID-19

June 5, 2020

BioSig Technologies’s PURE EP System to be Presented in Heart Rhythm Society 2020 Science Sessions

June 4, 2020

BioSig Technologies Expands Intellectual Property Portfolio

June 3, 2020

ViralClear to Host Conference Call on June 9th to Discuss Upcoming and Recent Developments for Phase II Human Clinical Trials of its Broad-Spectrum Oral Anti-viral Candidate for Treatment of COVID-19

June 1, 2020

Michael R. Dougherty Joins the Board of ViralClear Pharmaceuticals, a majority-owned subsidiary of BioSig Technologies, Inc.

May 28, 2020
RSS
    • 1
    • 2
    • 3
    • 4
    • 5
    • 6
    • 7
    • 8
    • 9
    • 10
    • ...24
    Award
    BioSig Technologies, Inc.
    Sign Up for BioSig Updates Contact Us
    Twitter linkedin Facebook
    © 2021 BioSig Technologies, Inc. All Rights Reserved.
    Privacy Policy Disclaimer Sitemap